Legacy Capital Partners Inc. decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,050 shares of the medical research company’s stock after selling 60 shares during the period. Legacy Capital Partners Inc.’s holdings in IQVIA were worth $254,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in IQV. Norges Bank bought a new position in IQVIA during the 4th quarter valued at approximately $330,676,000. Cantillon Capital Management LLC bought a new position in IQVIA during the 1st quarter valued at approximately $184,178,000. Credit Suisse AG raised its position in IQVIA by 8,868.0% during the 1st quarter. Credit Suisse AG now owns 850,346 shares of the medical research company’s stock valued at $164,235,000 after purchasing an additional 840,864 shares during the last quarter. FIL Ltd raised its holdings in IQVIA by 190.1% in the 1st quarter. FIL Ltd now owns 919,341 shares of the medical research company’s stock worth $177,562,000 after purchasing an additional 602,391 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in IQVIA by 88.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 981,645 shares of the medical research company’s stock worth $189,594,000 after purchasing an additional 459,394 shares in the last quarter. 86.31% of the stock is owned by institutional investors and hedge funds.
Shares of NYSE:IQV opened at $247.70 on Monday. The company’s 50 day moving average is $243.84. The company has a market cap of $47.46 billion, a P/E ratio of 79.39, a PEG ratio of 2.34 and a beta of 1.42. The company has a current ratio of 1.05, a quick ratio of 1.05 and a debt-to-equity ratio of 2.11. IQVIA Holdings Inc. has a 12-month low of $146.00 and a 12-month high of $254.05.
IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 27th. The medical research company reported $2.13 earnings per share for the quarter, topping the consensus estimate of $2.07 by $0.06. The company had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.27 billion. IQVIA had a net margin of 4.69% and a return on equity of 23.95%. IQVIA’s quarterly revenue was up 36.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.18 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 8.24 EPS for the current year.
Several research analysts have recently issued reports on the company. Citigroup increased their target price on IQVIA from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, July 28th. KeyCorp raised their target price on shares of IQVIA from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Friday, May 14th. Argus raised their price objective on IQVIA from $220.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, May 12th. Truist Securities raised their price target on IQVIA from $235.00 to $260.00 and gave the company a “buy” rating in a report on Monday, April 26th. Finally, Canaccord Genuity raised their price target on IQVIA from $220.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, May 12th. Two equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $255.53.
About IQVIA
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Story: Pattern Day Trader – What is the PDT Rule?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV).